National Center for Biotechnology Information, National Institutes of Health, 8600 Rockville Pike, Building 38A, Bethesda, MD 20894, USA.
J Mol Biol. 2012 Jan 13;415(2):443-53. doi: 10.1016/j.jmb.2011.12.026. Epub 2011 Dec 16.
The modulation of protein-protein interactions (PPIs) by small drug-like molecules is a relatively new area of research and has opened up new opportunities in drug discovery. However, the progress made in this area is limited to a handful of known cases of small molecules that target specific diseases. With the increasing availability of protein structure complexes, it is highly important to devise strategies exploiting homologous structure space on a large scale for discovering putative PPIs that could be attractive drug targets. Here, we propose a scheme that allows performing large-scale screening of all protein complexes and finding putative small-molecule and/or peptide binding sites overlapping with protein-protein binding sites (so-called "multibinding sites"). We find more than 600 nonredundant proteins from 60 protein families with multibinding sites. Moreover, we show that the multibinding sites are mostly observed in transient complexes, largely overlap with the binding hotspots and are more evolutionarily conserved than other interface sites. We investigate possible mechanisms of how small molecules may modulate protein-protein binding and discuss examples of new candidates for drug design.
小分子调节蛋白质-蛋白质相互作用(PPIs)是一个相对较新的研究领域,为药物发现开辟了新的机会。然而,这一领域的进展仅限于少数几种针对特定疾病的靶向小分子。随着越来越多的蛋白质结构复合物的出现,设计利用大规模同源结构空间的策略来发现可能成为有吸引力的药物靶点的假定 PPI 变得非常重要。在这里,我们提出了一种方案,允许对所有蛋白质复合物进行大规模筛选,并找到与蛋白质-蛋白质结合位点重叠的假定小分子和/或肽结合位点(所谓的“多结合位点”)。我们从 60 个蛋白质家族中发现了 600 多个非冗余蛋白质具有多结合位点。此外,我们表明,多结合位点主要存在于瞬态复合物中,与结合热点大部分重叠,并且比其他界面位点更具进化保守性。我们研究了小分子可能调节蛋白质-蛋白质结合的可能机制,并讨论了药物设计的新候选药物的例子。